Diüretik kullanımı sonrası deri nekrozu ile prezente olan staz dermatit

Kardiyovasküler hastalıkların tedavisinde önemli ilerlemeler kaydedilmesine rağmen periferik arter hastalığı (PAH) akut arteriyel tıkanmalar, ekstremiteyi tehdit eden iskemi ve vital organlarda fonksiyon kaybı meydana getirmesiyle önemini korumaktadır. Periferik arter hastalığının nedeni aterosklerozdur. Staz dermatiti, alt ekstremite kronik venöz yetmezliğinin en yaygın klinik şeklidir. Vakamızda dekompanse kalp yetmezliği tanılı hastada yoğun diüretik tedavi sonrası başlangıçta staz dermatiti şeklinde cilt lezyonu olan ve sonrasında periferik arter hastalığına bağlı deri nekrozu gelişimini sunduk. Risk faktörleri olan ileri yaş grubundaki hastalarda asemptomatik olsalar da PAH açısından tarama yapılarak erken tanıya ulaşmanın, hastaların prognozunu iyileştirmenin ve bu hastalarda dikkatli diüretik kullanımının önemine dikkat çekmeyi amaçladık.

Peripheral arterial disease presented with skin necrosis after diuretic use

Despite significant progress in the treatment of cardiovascular diseases, peripheral arterial disease (PAD) is of importance with acute arterial occlusions, ischemia that threatens the extremity and loss of function in the vital organs. The cause of peripheral artery disease is atherosclerosis. Stasis dermatitis is the most common form of the clinical manifestations of chronic venous insufficiency of the lower extremities. In our case, we presented the development of skin lesion in the form of stasis dermatitis at the beginning and then skin necrosis due to peripheral arterial disease after intensive diuretic therapy in a patient with a diagnosis of decompensated heart failure. We aimed to draw attention to the importance of early diagnosis by screening for PAH, improving the prognosis of patients, and careful use of diuretics in patients with risk factors, even if they are asymptomatic.

___

  • Campia, U., Gerhard-Herman, M., Piazza, G., & Goldhaber, S. Z. (2019). Peripheral artery disease: past, present, and future. The American Journal of Medicine, 132(10), 1133-1141.
  • Carone, L., Oxberry, S. G., Twycross, R., Charlesworth, S., Mihalyo, M., & Wilcock, A. (2016). Furosemide. Journal of Pain and Symptom Management, 52(1), 144-150.
  • Degertekin, M., Erol, Ç., Ergene, O., Tokgözoğlu, L., Aksoy, M., Erol, M. K., ... & Kozan, Ö. (2012). Heart failure prevalence and predictors in Turkey: HAPPY study. Archives of the Turkish Society of Cardiology, 40(4), 298-308.
  • Dworzynski, K., Roberts, E., Ludman, A., & Mant, J. (2014). Guideline development group of the national institute for health and care excellence. Diagnosing and managing acute heart failure in adults: summary of NICE guidance. BMJ, 349, g5695.
  • Ellison, D. H. (2019). Clinical pharmacology in diuretic use. Clinical Journal of the American Society of Nephrology, 14(8), 1248-1257.
  • Firnhaber, J. M., & Powell, C. S. (2019). Lower extremity peripheral artery disease: diagnosis and treatment. American Family Physician, 99(6), 362-369.
  • Heidenreich, P. A., Albert, N. M., Allen, L. A., Bluemke, D. A., Butler, J., Fonarow, G. C., ... & Trogdon, J. G. (2013). Forecasting the impact of heart failure in the United States: A policy statement from the American Heart Association. Circulation: Heart Failure, 6(3), 606-619.
  • Kurmani, S., & Squire, I. (2017). Acute heart failure: definition, classification and epidemiology. Current Heart Failure Reports, 14(5), 385-392.
  • Signorelli, S. S., Marino, E., Scuto, S., & Di Raimondo, D. (2020). Pathophysiology of Peripheral Arterial Disease (PAD): A review on oxidative disorders. International Journal of Molecular Sciences, 21(12), 4393.
  • Sundaresan, S., Migden, M. R., & Silapunt, S. (2017). Stasis dermatitis: pathophysiology, evaluation, and management. American Journal of Clinical Dermatology, 18(3), 383-390.